Is PHIO or MREO more profitable?

Mereo BioPharma Group's return on equity of -74.82% beat Phio Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Phio Pharmaceuticals N/A -87.41% -79.76% Mereo BioPharma Group N/A -74.82% -64.28%

Does the media refer more to PHIO or MREO?

In the previous week, Phio Pharmaceuticals had 1 more articles in the media than Mereo BioPharma Group. MarketBeat recorded 13 mentions for Phio Pharmaceuticals and 12 mentions for Mereo BioPharma Group. Mereo BioPharma Group's average media sentiment score of 0.49 beat Phio Pharmaceuticals' score of 0.32 indicating that Mereo BioPharma Group is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Phio Pharmaceuticals 0 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Mereo BioPharma Group 1 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend BKHA or PHIO?

Phio Pharmaceuticals has a consensus target price of $14.00, indicating a potential upside of 1,184.40%. Given Phio Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Phio Pharmaceuticals is more favorable than Black Hawk Acquisition. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Black Hawk Acquisition 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Phio Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has preferable earnings & valuation, BKHA or PHIO?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Black Hawk Acquisition N/A N/A N/A N/A N/A Phio Pharmaceuticals N/A N/A -$8.70M -$1.29 N/A

Is BKHA or PHIO more profitable?

Black Hawk Acquisition's return on equity of 0.00% beat Phio Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Black Hawk Acquisition N/A N/A N/A Phio Pharmaceuticals N/A -87.41% -79.76%

Do analysts rate TCRT or PHIO?

Phio Pharmaceuticals has a consensus price target of $14.00, indicating a potential upside of 1,184.40%. Given Phio Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Phio Pharmaceuticals is more favorable than Alaunos Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Alaunos Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Phio Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has higher earnings and valuation, TCRT or PHIO?

Alaunos Therapeutics is trading at a lower price-to-earnings ratio than Phio Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Alaunos Therapeutics N/A N/A -$4.18M -$2.13 N/A Phio Pharmaceuticals N/A N/A -$8.70M -$1.29 N/A

Is TCRT or PHIO more profitable?

Phio Pharmaceuticals' return on equity of -87.41% beat Alaunos Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Alaunos Therapeutics N/A -165.94% -123.50% Phio Pharmaceuticals N/A -87.41% -79.76%

Does the media refer more to PHIO or MCRB?

In the previous week, Phio Pharmaceuticals had 10 more articles in the media than Seres Therapeutics. MarketBeat recorded 13 mentions for Phio Pharmaceuticals and 3 mentions for Seres Therapeutics. Seres Therapeutics' average media sentiment score of 0.36 beat Phio Pharmaceuticals' score of 0.32 indicating that Seres Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Phio Pharmaceuticals 0 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Seres Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor PHIO or MGX?

In the previous week, Phio Pharmaceuticals had 7 more articles in the media than Metagenomi. MarketBeat recorded 13 mentions for Phio Pharmaceuticals and 6 mentions for Metagenomi. Phio Pharmaceuticals' average media sentiment score of 0.32 beat Metagenomi's score of -0.24 indicating that Phio Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Phio Pharmaceuticals 0 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Metagenomi 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Phio Pharmaceuticals (PHIO) Competitors

$1.09 0.00 (0.00%)

Closing price 04:00 PM Eastern

Extended Trading

$1.08 -0.01 (-0.46%)

As of 06:37 PM Eastern

Compare

PHIO vs. MREO, BKHA, TCRT, MCRB, and MGX

Should you buy Phio Pharmaceuticals stock or one of its competitors? Phio Pharmaceuticals's main competitors and comparable companies include Mereo BioPharma Group (MREO), Black Hawk Acquisition (BKHA), Alaunos Therapeutics (TCRT), Seres Therapeutics (MCRB), and Metagenomi (MGX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Phio Pharmaceuticals compare to Mereo BioPharma Group?

Phio Pharmaceuticals (NASDAQ:PHIO) and Mereo BioPharma Group (NASDAQ:MREO) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their risk, dividends, earnings, profitability, valuation, analyst recommendations, media sentiment and institutional ownership.

Phio Pharmaceuticals currently has a consensus target price of $14.00, suggesting a potential upside of 1,184.40%. Mereo BioPharma Group has a consensus target price of $3.25, suggesting a potential upside of 919.13%. Given Phio Pharmaceuticals' higher probable upside, equities analysts clearly believe Phio Pharmaceuticals is more favorable than Mereo BioPharma Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Phio Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Mereo BioPharma Group	1 Sell rating(s)	4 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.25

Phio Pharmaceuticals has a beta of 0.82, suggesting that its stock price is 18% less volatile than the broader market. Comparatively, Mereo BioPharma Group has a beta of 0.36, suggesting that its stock price is 64% less volatile than the broader market.

In the previous week, Phio Pharmaceuticals had 1 more articles in the media than Mereo BioPharma Group. MarketBeat recorded 13 mentions for Phio Pharmaceuticals and 12 mentions for Mereo BioPharma Group. Mereo BioPharma Group's average media sentiment score of 0.49 beat Phio Pharmaceuticals' score of 0.32 indicating that Mereo BioPharma Group is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Phio Pharmaceuticals	0 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Mereo BioPharma Group	1 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Phio Pharmaceuticals has higher earnings, but lower revenue than Mereo BioPharma Group. Mereo BioPharma Group is trading at a lower price-to-earnings ratio than Phio Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Phio Pharmaceuticals	N/A	N/A	-$8.70M	-$1.29	N/A
Mereo BioPharma Group	$500K	101.81	-$41.88M	-$0.05	N/A

57.3% of Phio Pharmaceuticals shares are owned by institutional investors. Comparatively, 62.8% of Mereo BioPharma Group shares are owned by institutional investors. 0.9% of Phio Pharmaceuticals shares are owned by insiders. Comparatively, 6.5% of Mereo BioPharma Group shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Mereo BioPharma Group's return on equity of -74.82% beat Phio Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Phio Pharmaceuticals	N/A	-87.41%	-79.76%
Mereo BioPharma Group	N/A	-74.82%	-64.28%

Summary

Mereo BioPharma Group beats Phio Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

How does Phio Pharmaceuticals compare to Black Hawk Acquisition?

Black Hawk Acquisition (NASDAQ:BKHA) and Phio Pharmaceuticals (NASDAQ:PHIO) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, risk, dividends, media sentiment, profitability, institutional ownership and valuation.

57.3% of Phio Pharmaceuticals shares are owned by institutional investors. 0.9% of Phio Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Black Hawk Acquisition	N/A	N/A	N/A	N/A	N/A
Phio Pharmaceuticals	N/A	N/A	-$8.70M	-$1.29	N/A

Phio Pharmaceuticals has a consensus target price of $14.00, indicating a potential upside of 1,184.40%. Given Phio Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Phio Pharmaceuticals is more favorable than Black Hawk Acquisition.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Black Hawk Acquisition	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Phio Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Black Hawk Acquisition's return on equity of 0.00% beat Phio Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Black Hawk Acquisition	N/A	N/A	N/A
Phio Pharmaceuticals	N/A	-87.41%	-79.76%

Black Hawk Acquisition has a beta of 0.04, indicating that its stock price is 96% less volatile than the broader market. Comparatively, Phio Pharmaceuticals has a beta of 0.82, indicating that its stock price is 18% less volatile than the broader market.

In the previous week, Phio Pharmaceuticals had 12 more articles in the media than Black Hawk Acquisition. MarketBeat recorded 13 mentions for Phio Pharmaceuticals and 1 mentions for Black Hawk Acquisition. Black Hawk Acquisition's average media sentiment score of 1.87 beat Phio Pharmaceuticals' score of 0.32 indicating that Black Hawk Acquisition is being referred to more favorably in the media.

Company	Overall Sentiment
Black Hawk Acquisition	Very Positive
Phio Pharmaceuticals	Neutral

Summary

Phio Pharmaceuticals beats Black Hawk Acquisition on 7 of the 10 factors compared between the two stocks.

How does Phio Pharmaceuticals compare to Alaunos Therapeutics?

Alaunos Therapeutics (NASDAQ:TCRT) and Phio Pharmaceuticals (NASDAQ:PHIO) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, media sentiment, risk, institutional ownership, profitability and analyst recommendations.

Phio Pharmaceuticals' return on equity of -87.41% beat Alaunos Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alaunos Therapeutics	N/A	-165.94%	-123.50%
Phio Pharmaceuticals	N/A	-87.41%	-79.76%

In the previous week, Phio Pharmaceuticals had 11 more articles in the media than Alaunos Therapeutics. MarketBeat recorded 13 mentions for Phio Pharmaceuticals and 2 mentions for Alaunos Therapeutics. Alaunos Therapeutics' average media sentiment score of 1.87 beat Phio Pharmaceuticals' score of 0.32 indicating that Alaunos Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Alaunos Therapeutics	Very Positive
Phio Pharmaceuticals	Neutral

Alaunos Therapeutics has a beta of -1, suggesting that its stock price is 200% less volatile than the broader market. Comparatively, Phio Pharmaceuticals has a beta of 0.82, suggesting that its stock price is 18% less volatile than the broader market.

Phio Pharmaceuticals has a consensus price target of $14.00, indicating a potential upside of 1,184.40%. Given Phio Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Phio Pharmaceuticals is more favorable than Alaunos Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alaunos Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Phio Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

27.7% of Alaunos Therapeutics shares are owned by institutional investors. Comparatively, 57.3% of Phio Pharmaceuticals shares are owned by institutional investors. 16.1% of Alaunos Therapeutics shares are owned by insiders. Comparatively, 0.9% of Phio Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Alaunos Therapeutics is trading at a lower price-to-earnings ratio than Phio Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alaunos Therapeutics	N/A	N/A	-$4.18M	-$2.13	N/A
Phio Pharmaceuticals	N/A	N/A	-$8.70M	-$1.29	N/A

Summary

Phio Pharmaceuticals beats Alaunos Therapeutics on 10 of the 13 factors compared between the two stocks.

How does Phio Pharmaceuticals compare to Seres Therapeutics?

Phio Pharmaceuticals (NASDAQ:PHIO) and Seres Therapeutics (NASDAQ:MCRB) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, profitability, media sentiment, institutional ownership, dividends, valuation and risk.

In the previous week, Phio Pharmaceuticals had 10 more articles in the media than Seres Therapeutics. MarketBeat recorded 13 mentions for Phio Pharmaceuticals and 3 mentions for Seres Therapeutics. Seres Therapeutics' average media sentiment score of 0.36 beat Phio Pharmaceuticals' score of 0.32 indicating that Seres Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Phio Pharmaceuticals	0 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Seres Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

57.3% of Phio Pharmaceuticals shares are owned by institutional investors. Comparatively, 59.3% of Seres Therapeutics shares are owned by institutional investors. 0.9% of Phio Pharmaceuticals shares are owned by insiders. Comparatively, 5.2% of Seres Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Seres Therapeutics has higher revenue and earnings than Phio Pharmaceuticals. Seres Therapeutics is trading at a lower price-to-earnings ratio than Phio Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Phio Pharmaceuticals	N/A	N/A	-$8.70M	-$1.29	N/A
Seres Therapeutics	$790K	57.12	$5.70M	-$2.43	N/A

Phio Pharmaceuticals has a beta of 0.82, indicating that its stock price is 18% less volatile than the broader market. Comparatively, Seres Therapeutics has a beta of 0.2, indicating that its stock price is 80% less volatile than the broader market.

Phio Pharmaceuticals has a net margin of 0.00% compared to Seres Therapeutics' net margin of -1,192.94%. Phio Pharmaceuticals' return on equity of -87.41% beat Seres Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Phio Pharmaceuticals	N/A	-87.41%	-79.76%
Seres Therapeutics	-1,192.94%	-114.82%	-34.15%

Phio Pharmaceuticals currently has a consensus target price of $14.00, indicating a potential upside of 1,184.40%. Seres Therapeutics has a consensus target price of $17.00, indicating a potential upside of 274.45%. Given Phio Pharmaceuticals' higher probable upside, research analysts clearly believe Phio Pharmaceuticals is more favorable than Seres Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Phio Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Seres Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Summary

Seres Therapeutics beats Phio Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

How does Phio Pharmaceuticals compare to Metagenomi?

Phio Pharmaceuticals (NASDAQ:PHIO) and Metagenomi (NASDAQ:MGX) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their risk, profitability, dividends, media sentiment, institutional ownership, valuation, earnings and analyst recommendations.

Phio Pharmaceuticals presently has a consensus price target of $14.00, indicating a potential upside of 1,184.40%. Metagenomi has a consensus price target of $6.33, indicating a potential upside of 414.91%. Given Phio Pharmaceuticals' higher possible upside, research analysts clearly believe Phio Pharmaceuticals is more favorable than Metagenomi.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Phio Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Metagenomi	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80

Phio Pharmaceuticals has a beta of 0.82, suggesting that its share price is 18% less volatile than the broader market. Comparatively, Metagenomi has a beta of 0.66, suggesting that its share price is 34% less volatile than the broader market.

Phio Pharmaceuticals has a net margin of 0.00% compared to Metagenomi's net margin of -384.61%. Metagenomi's return on equity of -63.65% beat Phio Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Phio Pharmaceuticals	N/A	-87.41%	-79.76%
Metagenomi	-384.61%	-63.65%	-44.52%

In the previous week, Phio Pharmaceuticals had 7 more articles in the media than Metagenomi. MarketBeat recorded 13 mentions for Phio Pharmaceuticals and 6 mentions for Metagenomi. Phio Pharmaceuticals' average media sentiment score of 0.32 beat Metagenomi's score of -0.24 indicating that Phio Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Phio Pharmaceuticals	0 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Metagenomi	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Phio Pharmaceuticals has higher earnings, but lower revenue than Metagenomi. Phio Pharmaceuticals is trading at a lower price-to-earnings ratio than Metagenomi, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Phio Pharmaceuticals	N/A	N/A	-$8.70M	-$1.29	N/A
Metagenomi	$25.21M	1.84	-$87.87M	-$2.49	N/A

57.3% of Phio Pharmaceuticals shares are owned by institutional investors. 0.9% of Phio Pharmaceuticals shares are owned by company insiders. Comparatively, 12.5% of Metagenomi shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Phio Pharmaceuticals and Metagenomi tied by winning 8 of the 16 factors compared between the two stocks.

Get Phio Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PHIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PHIO vs. The Competition

Export

Metric	Phio Pharmaceuticals	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$12.66M	$3.74B	$7.06B	$13.10B
Dividend Yield	N/A	3.70%	2.57%	10.45%
P/E Ratio	-0.84	10.67	269.06	25.28
Price / Sales	N/A	1,275.04	592.96	87.71
Price / Cash	N/A	102.88	70.48	50.90
Price / Book	1.01	16.78	12.91	6.24
Net Income	-$8.70M	-$13.32M	$3.45B	$347.60M
7 Day Performance	4.81%	1.74%	1.12%	1.07%
1 Month Performance	5.83%	1.60%	1.79%	1.03%
1 Year Performance	-50.23%	56.43%	67.69%	20.77%

Phio Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PHIO Phio Pharmaceuticals	3.406 of 5 stars	$1.09 flat	$14.00 +1,184.4%	-50.2%	$12.66M	N/A	N/A	10	News Coverage Short Interest Increase Analyst Revision Gap Up
MREO Mereo BioPharma Group	3.2393 of 5 stars	$0.31 +14.9%	$3.25 +938.3%	-82.2%	$49.96M	$500K	N/A	40	News Coverage Earnings Report Analyst Forecast Gap Down High Trading Volume
BKHA Black Hawk Acquisition	N/A	$11.90 +1.0%	N/A	+8.5%	$49.36M	N/A	N/A	N/A
TCRT Alaunos Therapeutics	1.3379 of 5 stars	$1.97 -0.5%	N/A	-16.7%	$48.13M	N/A	N/A	40	Positive News Earnings Report Upcoming Earnings
MCRB Seres Therapeutics	2.5616 of 5 stars	$4.66 -6.9%	$17.00 +265.2%	-71.9%	$46.28M	$1.88M	N/A	330	Analyst Downgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PHIO) was last updated on 8/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Phio Pharmaceuticals (PHIO) Competitors

PHIO vs. MREO, BKHA, TCRT, MCRB, and MGX

How does Phio Pharmaceuticals compare to Mereo BioPharma Group?

Summary

How does Phio Pharmaceuticals compare to Black Hawk Acquisition?

Summary

How does Phio Pharmaceuticals compare to Alaunos Therapeutics?

Summary

How does Phio Pharmaceuticals compare to Seres Therapeutics?

Summary

How does Phio Pharmaceuticals compare to Metagenomi?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PHIO vs. The Competition

Phio Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Phio Pharmaceuticals (PHIO) Competitors

PHIO vs. MREO, BKHA, TCRT, MCRB, and MGX

How does Phio Pharmaceuticals compare to Mereo BioPharma Group?

Do analysts recommend PHIO or MREO?

Which has more volatility and risk, PHIO or MREO?

Does the media refer more to PHIO or MREO?

Which has preferable valuation & earnings, PHIO or MREO?

Do institutionals & insiders hold more shares of PHIO or MREO?

Is PHIO or MREO more profitable?

Summary

How does Phio Pharmaceuticals compare to Black Hawk Acquisition?

Do insiders and institutionals believe in BKHA or PHIO?

Which has preferable earnings & valuation, BKHA or PHIO?

Do analysts recommend BKHA or PHIO?

Is BKHA or PHIO more profitable?

Which has more volatility & risk, BKHA or PHIO?

Does the media favor BKHA or PHIO?

Summary

How does Phio Pharmaceuticals compare to Alaunos Therapeutics?

Is TCRT or PHIO more profitable?

Does the media favor TCRT or PHIO?

Which has more risk & volatility, TCRT or PHIO?

Do analysts rate TCRT or PHIO?

Do institutionals & insiders hold more shares of TCRT or PHIO?

Which has higher earnings and valuation, TCRT or PHIO?

Summary

How does Phio Pharmaceuticals compare to Seres Therapeutics?

Does the media refer more to PHIO or MCRB?

Do insiders & institutionals believe in PHIO or MCRB?

Which has stronger valuation & earnings, PHIO or MCRB?

Which has more volatility and risk, PHIO or MCRB?

Is PHIO or MCRB more profitable?

Do analysts prefer PHIO or MCRB?

Summary

How does Phio Pharmaceuticals compare to Metagenomi?

Do analysts recommend PHIO or MGX?

Which has more risk and volatility, PHIO or MGX?

Is PHIO or MGX more profitable?

Does the media favor PHIO or MGX?

Which has stronger earnings & valuation, PHIO or MGX?

Do insiders and institutionals believe in PHIO or MGX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PHIO vs. The Competition

Phio Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools